Kyriakos Peter Papadopoulos MD
Senior Clinical Investigator at START in San Antonio
Join to View Full Profile
4383 Medical DrSan Antonio, TX 78229
Phone+1 210-593-5700
Fax+1 210-593-5992
Are you Dr. Papadopoulos?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kyriakos Papadopoulos, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 1999- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1994 - 1997
University of the WitwatersrandClass of 1985
Certifications & Licensure
TX State Medical License 2004 - 2025
NY State Medical License 1997 - 2006
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Fusion oncoproteins and cooperating mutations define disease phenotypes in-rearranged leukemia.Masayuki Umeda, Ryan Hiltenbrand, Nicole L Michmerhuizen, Juan M Barajas, Melvin E Thomas
Medrxiv. 2025-01-22 - First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16 - First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F Garrido
Clinical Cancer Research. 2024-12-16
Press Mentions
START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
FDA Grants Cemiplimab Breakthrough Designation for CSCCSeptember 8th, 2017
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual MeetingJune 4th, 2017- Join now to see all
